AbCellera Biologics Inc.
General ticker "ABCL" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $1.0B (TTM average)
AbCellera Biologics Inc. follows the US Stock Market performance with the rate: 58.0%.
Estimated limits based on current volatility of 3.0%: low 3.43$, high 3.64$
Factors to consider:
- Total employees count: 596 (+1.7%) as of 2024
- US accounted for 9.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Fluctuating operating results, Economic downturns and volatility, Regulatory and compliance, Supply chain disruptions, Market competition
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.81$, 4.44$]
- 2025-12-31 to 2026-12-31 estimated range: [1.77$, 4.33$]
Financial Metrics affecting the ABCL estimates:
- Positive: with PPE of -5.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.82 <= 0.33
- Positive: Shareholder equity ratio, % of 77.62 > 63.39
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ABCL quotes
Long-term ABCL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $485.42MM | $38.02MM | $28.83MM |
| Operating Expenses | $268.91MM | $275.23MM | $343.60MM |
| Operating Income | $216.51MM | $-237.21MM | $-314.77MM |
| Non-Operating Income | $22.59MM | $63.18MM | $114.37MM |
| R&D Expense | $107.88MM | $175.66MM | $167.26MM |
| Income(Loss) | $239.10MM | $-174.03MM | $-200.40MM |
| Taxes | $80.58MM | $-27.63MM | $-37.54MM |
| Profit(Loss)* | $158.52MM | $-146.40MM | $-162.86MM |
| Stockholders Equity | $1,233.28MM | $1,152.32MM | $1,056.08MM |
| Inventory | $1.53MM | $1.11MM | $0.00MM |
| Assets | $1,540.91MM | $1,488.09MM | $1,360.55MM |
| Operating Cash Flow | $277.36MM | $-43.88MM | $-108.56MM |
| Capital expenditure | $72.66MM | $77.51MM | $78.40MM |
| Investing Cash Flow | $-352.62MM | $-221.11MM | $121.41MM |
| Financing Cash Flow | $-1.63MM | $10.36MM | $12.77MM |
| Earnings Per Share** | $0.56 | $-0.51 | $-0.55 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.